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Copyright © 2008 JCBN Summary Proton pump inhibitors (PPIs) are novel compounds that strongly inhibit the H+/K+-
ATPase in the gastric parietal cells to cause profound suppression of acid secretion. Acid-
generating ATPase, also known as vacuolar-type ATPase, is located in the lysozomes of leuko-
cytes and osteoclasts and its activity is also reportedly influenced by treatment with PPIs. This
concept is supported by the results of studies using autoradiography in which 3H-Lansoprazole
uptake sites were clearly detected in the cytoplasmic granules of neutrophils infiltrating the
gastric mucosa. In vitro studies indicate that PPIs increase the intra-vacuolar pH in the
lysosomes of purified neutrophils and attenuate the adherence of neutrophils to the vascular
endothelium. In clinical practice, the acidic environment in the stomach plays a critical role
in the development of gastritis induced by Helicobacter pylori (H. pylori). This is worthy of note,
because persistent gastritis often results in atrophic and metaplastic changes in the gastric
mucosa, which are believed to be preneoplastic abnormalities. In patients with H. pylori-
infection, PPI therapy causes corpus-predominant gastritis, which is frequently found in the
background mucosa in patients with gastric cancer. The efficacy and safety of long-term PPI-
treatment have not been conclusive, thus we need to pay more attention to the additional
pharmacological actions of PPIs.
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Introduction
Gastric H+/K+-ATPase is a key proton pump that
exchanges hydrogen (H+) and potassium (K+) ions across
the canalicular membrane in acid-secreting parietal cells.
Proton pump inhibitors (PPIs) (omeprazole, lansoprazole,
rabeprazole and pantoprazole) are initially absorbed via the
small intestine and distributed to the gastric parietal cells,
where they are activated in the acidic environment of their
acidic vesicles and secretory canaliculi. Profound acidity
(pH < 1) is reportedly necessary for the activation of PPIs,
thus it has been believed that parietal cells are the only sites
in the human body in which PPIs are activated. However,
cells such as leukocytes and osteoclasts are also known to
have acidic vesicles in their cytoplasm. The pump in these
cells is known as vacuolar-type H+-ATPase, different from
gastric H+/K+-ATPase (Table 1). If PPIs indeed exertedM. Suzuki et al.
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effects on the functions of these cells, additional interesting
therapeutic possibilities may be revealed for PPIs. However,
we would also need to pay attention to the adverse effects of
long-term and high-dose PPI therapy.
More than half of the Japanese population is reported to
be infected with Helicobacter pylori (H. pylori). Unfortu-
nately, Japanese National Health Insurance does not cover
treatment of asymptomatic H. pylori infection, even though
gastric cancer has clearly been demonstrated to be associated
with  H. pylori infection. Corpus-predominant gastritis is
known as a high-risk gastritis pattern in relation to the
development of gastric cancer, and is sometimes promoted
by treatment with antisecretory drugs.
Effects of PPIs on Cellular Functions
The actions of PPIs on the functions of cells other than
parietal cells have not been well studied. Wandall et al. [1]
reported that omeprazole exerts effects on neutrophil
chemotaxis, degranulation and superoxide production. It has
also been demonstrated that oxygen-derived free radical
production from activated neutrophils is inhibited by lanso-
prazole in vitro, and by an autoradiographic study, that 3H-
lansoprazole-binding sites are present in the cytoplasmic
granules of neutrophils infiltrating the gastric mucosa; also,
omeprazole was reported to attenuate the adherence of
neutrophils to the venular endothelium of the rat mesentery
[2, 3]. Yoshida et al. [4] reported that expression of integrins
(CD11b and CD18) in activated neutrophils was attenuated
by omeprazole and lansoprazole. The molecular mecha-
nisms by which PPIs affect the neutrophil functions have not
yet been fully elucidated. NADPH-oxidase (oxidant-
producing enzyme) and integrins (adherence molecule) are
membrane-bound enzymes that are activated by fusion of
the lysosomal membrane. Acidification of lysosomes is also
achieved by fusion of the cytoplasmic vesicles. Thus, the
effects of PPIs on the functions of neutrophils may be
associated with lysosomal dysfunction. To explore the
underlying mechanisms, we examined the effects of PPIs on
the lysosomal pH of purified neutrophils activated by f-
methionyl-leucyl-phenylalanine (FMLP) and opsonized
zymosan by assessing the fluerescence intensity ratio of
phagocytosed FITC-dextran using digital-fluorescence video
microscopy. The results revealed that the lysosomal pH
increased in a dose-dependent manner by pretreatment with
omeprazole (1–100 µM) (Table 2) [5]; the intralysosomal
pH in the absence of omeprazole was 5.81, which was not
sufficient for activation of omeprazole, because the pKa of
omeprazole is about 4.0, while the pH in the cytoplasmic
vesicles that subsequently translocated to secondary lyso-
somes was estimated to be more acidic (pH < 3). If leukocyte
dysfunction is evoked by PPIs, the bactericidal functions of
the cells may be affected. This possibility is supported by a
recent clinical report indicating that the prevalence of
pneumonia was significantly increased in a subject popula-
tion administered PPI therapy [6].
An acid-secreting proton pump is also expressed on the
plasma membrane of bone-resorbing osteoclasts, and also of
macrophages and kidney epithelial intercalated cells [7–9].
This pump mediates the acidification of the extracellular
environment and belongs to the family of vacuolar-type H+-
ATPases [10]. Visentin et al. [ 11] reported that a novel
Table 1. Characteristics of acid-generating ATPase
Parietal cell H+/K+-ATPase Vacuolar H+-ATPase
Location Stomach Osteoclasts
(parietal cell) Leukocytes
Kidney epithelial cells
Physiological role Secretion of gastric acid Bone resorption
Phagocytosis
Acidification of urine
Potent inhibitor Proton pump inhibitor Bafilomycin A1
Level of acidity (pH) <1 3–6
Table 2. Effect of omeprazole (OPZ) on the intralysosomal pH in purified human neutrophil as estimated from the FITC-
fluorescence ratio. Data indicate mean ± SD. *p<0.05 and **p<0.001, compared with the control value. Reprinted
with permission [5]
Control 
(n = 12)
OPZ 10−6 M 
(n = 12)
OPZ 10−5 M 
(n =1 2 )
OPZ 10−4 M 
(n = 12)
Fluorescence ratio (495 nm/420 nm) 0.245 ± 0.017 0.280 ± 0.018 0.303 ± 0.023* 0.351 ± 0.019**
Estimated intralysosomal pH 5.81 ± 0.09 6.00 ± 0.09 6.12 ± 0.12* 6.37 ± 0.10**Proton Pump Inhibitor and Gastritis
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selective inhibitor of the osteoclastic v-type ATPase pre-
vented bone loss in rats. Although the osteoclast v-type
ATPase is different from the parietal H+/K+-ATPase,
Tuukkanen et al. [12] reported that omeprazole also inhibits
bone resorption in vitro. In a trial conducted by Mizunashi
et al. [13], omeprazole changed bone resorption parameters,
such as the urinary hydroxyproline and calcium levels,
suggesting that it can suppress bone resorption. These data
indicate the possible efficacy of PPIs in the treatment of
osteoporosis to prevent bone fractures. However, a recent
case-control study demonstrated that the risk of hip fracture
was increased in patients on long-term PPI therapy [14].
These results suggest that the potentially protective effect of
osteoclatic proton pump inhibition may attenuate some of
the negative effects of gastric acid suppression of PPIs,
including on calcium absorption.
Clinical Implications of PPI Treatment on the Devel-
opment of Gastritis
The effects of PPI treatment on mucosal inflammation in
the stomach are quite complex. The severity of gastritis is
simply influenced by the acidity of the environment and
leukocyte activity, and both are attenuated by PPIs, as
described before. It is generally accepted that H. pylori is the
most commonly encountered pathogen in cases of gastritis.
PPIs reportedly inhibit not only the bioactivity of H. pylori,
but also its urease activity which is important for bacterial
survival in the acidic environment [15, 16]. These in vitro
observations are supported by clinical evidence: it was
demonstrated that the whole intragastric urease activity as
assessed by the urea breath test (UBT), was attenuated by
treatment with PPIs [17]. However, Logan et al. found that
treatment of H. pylori-infected gastritis with PPIs (omepra-
zole, 4 weeks) improved the histological severity of gastritis
in the antrum, but not in the corpus [18]. This observation is
compatible with the author’s data that the myeloperoxidase
content, a quantitative measure of neutrophil infiltration,
decreased in the antral mucosa, but significantly increased in
the corpus mucosa in patients with H. pylori-infected
antrum-predominant gastritis [19]. Interestingly, the bacterial
density of H. pylori decreased in the antrum, but remained
unchanged in the corpus after PPI therapy. This observation
implies that the aggravated corpus gastritis was not due to
increased bacterial intensity. Although the mechanism is still
unclear, several possibilities are postulated. The first
possibility is involvement of the chemotactic molecule,
monochloramine. Monochloramine is synthesized by the
reaction of ammonia with hypochlorite derived from
activated neutrophils [20], and its synthesis is promoted as
the pH rises. Thus, treatment with PPIs may aggravate
monochloramine-dependent corpus gastritis. The second
possibility is closer contact between the bacteria and the
gastric mucosa sensitive to immune inflammatory responses;
deep invasion of H. pylori into the gastric pits may evoke
strong inflammatory reaction. However, little evidence
supporting this phenomenon has been reported so far.
Kuipers  et al. [ 21] reported the important finding that
atrophic gastritis was promoted in H. pylori-infected
patients treated with omeprazole for a long time. Since
atrophic change of the gastric mucosa has been believed to
be a precancerous lesion, this report has attracted much
attention. It is acknowledged that atrophy is the final stage
of mucosal inflammation, thus progression to atrophy is
associated with the enhanced inflammation evoked by PPI
treatment. Authors found that 8-week treatment with PPIs
elicited a 2-fold increase in oxidative stress in the corpus
mucosa, although only a 10–20% increase was observed
in the mucosal contents of myeloperoxidase and IL-8
(Fig. 1) [22]. Oxidative stress was further increased after
long-term (24 weeks) treatment with lansoprazole [23].
Corpus-predominant gastritis is known as a high-risk factor
for the development of gastric cancer [24]. Thus, we must
pay attention to the risk of carcinogenic mutations in H.
pylori-infected patients receiving PPI therapy. No system-
atic clinical trials have been performed to elucidate the
relative cancer risk of PPI therapy in H. pylori-infected
subjects. Hypergastrinemia, which is frequently induced by
PPIs, is thought to be another potent risk factor for carcino-
genesis. Thus, we need to carefully follow the changes in the
gastric mucosa after PPI administration unless anti-H. pylori
therapy is successful. The efficacy of PPIs on non-H. pylori-
related mucosal inflammation remains unclear. It has been
Fig. 1. Effect of proton pump inhibitors (PPIs) on the luminol-
dependent chemiluminescense (ChL) activity in H.
pylori-infected patients (n = 34). The antral ChL
remained unchanged after PPI treatment, while a signifi-
cant increase was observed in the corpus ChL value.
*p<0.02, compared with the pretreatment value. Reprint
with permission [22].M. Suzuki et al.
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demonstrated that treatment with lansoprazole reduces the
mucosal inflammation in esophagus with gastro-esophageal
reflux disease (GERD) [25,  26]. The authors found that
the oxidative stress in the ulcer scar portion in H. pylori-
negative patients was significantly decreased in patients
treated with PPIs as compared with that in patients not
treated with PPIs (Fig. 2) [27]. Ulcer relapse is associated
with focal inflammation, therefore PPI therapy may be useful
to promote ulcer healing in H. pylori-negative subjects.
Conclusions
PPIs may modulate not only gastric H+/K+-ATPase
activity, but also v-type H+-ATPase activity, which is widely
distributed in a variety of cells in the human body. Among
these, the acid-producing systems in osteoclasts and leuko-
cytes are well developed for maintaining bone turnover and
exhibit bactericidal roles and promote tissue-destructive
inflammation. Therefore, there is still much potential for
research on the pharmacological and clinical aspects of PPI
treatment.
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